SCHEMBL30765784

SCHEMBL30765784

CC(C)(C)OC(=O)Cn1c(-c2ccc(OC3COC3)cc2)ncc(NCc2ccc3oc4ccccc4c3c2)c1=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
LMNA P02545 4/20 0.35
ALDH1A1 P00352 5/20 0.34
KDM4E B2RXH2 3/20 0.34
TP53 P04637 1/20 0.34
MAPT P10636 4/20 0.33
HPGD P15428 4/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
HCRTR1 O43613 2/20 0.33
HCRTR2 O43614 2/20 0.33
CASP1 P29466 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
PTGER4 P35408 1/20 0.33
ELANE P08246 1/20 0.32
BCHE P06276 1/20 0.32
CNR2 P34972 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765805 0.90 LMNA (0.39) NPSR1RXFP1LMNAALDH1A1KDM4E
SCHEMBL30766100 0.89 GAA (0.42) NPSR1RXFP1LMNAALDH1A1KDM4E
SCHEMBL30765948 0.86 LMNA (0.39) NPSR1RXFP1LMNAELANEBCHE
SCHEMBL30765442 0.82 ELANE (0.38) NPSR1RXFP1LMNAALDH1A1KDM4E
SCHEMBL30765604 0.81 AVPR1B (0.34) CASP1
SCHEMBL30765914 0.81 ELANE (0.39) ALDH1A1KDM4EELANE
SCHEMBL30765777 0.80 HCRTR1 (0.40) NPSR1RXFP1LMNAALDH1A1KDM4E
SCHEMBL30765705 0.79 ALDH1A1 (0.38) NPSR1RXFP1LMNAALDH1A1KDM4E
SCHEMBL30765836 0.79 KDM4E (0.36) LMNAALDH1A1KDM4EMAPTHPGD
SCHEMBL30765838 0.77 CASP1 (0.41) LMNAKDM4EHPGDCASP1ELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed